Modern strategies in therapy of elderly patients with multiple myeloma
We used the bortezomib plus dexamethasone (VD) and bortezomib plus MP (VMP) in 56 previously untreated elderly patients with multiple myeloma. The patients were 65–89 years old. For patients who received bortezomib plus MP the overall response rate was 83%. 33.3% of patients achieved complete respon...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/757 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850024463894052864 |
|---|---|
| author | S. S. Bessmeltsev L. V. Stelmashenko E. V. Kariagina N. V. Stepanova G. N. Salogub T. L. Shelkovskaya T. A. Malakhova I. A. Skorokhod E. I. Podoltseva N. O. Saraeva O. I. Kovalev A. V. Klimovich N. V. Medvedeva K. M. Abdulkadyrov L. I. Krylova T. H. Potrachkova M. A. Novikova E. R. Machulaitene E. I. Darskaya L. M. Matukhina N. A. Kotova O. Ya. Kostina I. A. Novokreshchenova |
| author_facet | S. S. Bessmeltsev L. V. Stelmashenko E. V. Kariagina N. V. Stepanova G. N. Salogub T. L. Shelkovskaya T. A. Malakhova I. A. Skorokhod E. I. Podoltseva N. O. Saraeva O. I. Kovalev A. V. Klimovich N. V. Medvedeva K. M. Abdulkadyrov L. I. Krylova T. H. Potrachkova M. A. Novikova E. R. Machulaitene E. I. Darskaya L. M. Matukhina N. A. Kotova O. Ya. Kostina I. A. Novokreshchenova |
| author_sort | S. S. Bessmeltsev |
| collection | DOAJ |
| description | We used the bortezomib plus dexamethasone (VD) and bortezomib plus MP (VMP) in 56 previously untreated elderly patients with multiple myeloma. The patients were 65–89 years old. For patients who received bortezomib plus MP the overall response rate was 83%. 33.3% of patients achieved complete response (near-complete response + complete response) (based on EBMT criteria). For patients who received bortezomib plus dexamethasone the overall response rate was 73%. 34.6% of patients achieved complete response. Median overall survival in patients treated with bortezomib plus dexamethasone and bortezomib plus MP has not been reached. Median event-free survival was 15 and 17 months respectively. Side effects of bortezomib were predictable and manageable. The most common adverse events reported were asthenia, neuropathy, neutropenia and anemia. Serious adverse events were rare. These results establish VMP and VD as modern strategies in therapy of elderly untreated patients with multiple myeloma. VMP and VD is highly effective and well tolerated in elderly patients (> 65 years) with newly diagnosed multiple myeloma. |
| format | Article |
| id | doaj-art-c2efdc3ba2154cfb809d445aa9adf43d |
| institution | DOAJ |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2022-11-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-c2efdc3ba2154cfb809d445aa9adf43d2025-08-20T03:01:06ZrusABV-pressОнкогематология1818-83462413-40232022-11-0104613635Modern strategies in therapy of elderly patients with multiple myelomaS. S. Bessmeltsev0L. V. Stelmashenko1E. V. Kariagina2N. V. Stepanova3G. N. Salogub4T. L. Shelkovskaya5T. A. Malakhova6I. A. Skorokhod7E. I. Podoltseva8N. O. Saraeva9O. I. Kovalev10A. V. Klimovich11N. V. Medvedeva12K. M. Abdulkadyrov13L. I. Krylova14T. H. Potrachkova15M. A. Novikova16E. R. Machulaitene17E. I. Darskaya18L. M. Matukhina19N. A. Kotova20O. Ya. Kostina21I. A. Novokreshchenova22Russian Research Institute of Hematology and TransfusiologyRussian Research Institute of Hematology and TransfusiologyCity Hospital 15St.-Petersburg State Pavlov Medical UniversitySt.-Petersburg State Pavlov Medical UniversityCity Hospital 15City Hospital 15City Hospital 31City Hospital 31Irkutsk Region Clinic Hospital; Irkutsk State Medical UniversityDepartment of Hospital in station SmolenskCity Hospital 31City Hospital 31Russian Research Institute of Hematology and TransfusiologyCity Hospital 15Irkutsk Region Clinic HospitalDepartment of Hospital in station SmolenskSt.-Petersburg State Pavlov Medical UniversityRaisa Gorbacheva Memorial Institute of Pediatric Hematology and TransplantologyRoad Clinic HospitalCity Hospital 31Road Clinic HospitalDepartment of Hospital in station SmolenskWe used the bortezomib plus dexamethasone (VD) and bortezomib plus MP (VMP) in 56 previously untreated elderly patients with multiple myeloma. The patients were 65–89 years old. For patients who received bortezomib plus MP the overall response rate was 83%. 33.3% of patients achieved complete response (near-complete response + complete response) (based on EBMT criteria). For patients who received bortezomib plus dexamethasone the overall response rate was 73%. 34.6% of patients achieved complete response. Median overall survival in patients treated with bortezomib plus dexamethasone and bortezomib plus MP has not been reached. Median event-free survival was 15 and 17 months respectively. Side effects of bortezomib were predictable and manageable. The most common adverse events reported were asthenia, neuropathy, neutropenia and anemia. Serious adverse events were rare. These results establish VMP and VD as modern strategies in therapy of elderly untreated patients with multiple myeloma. VMP and VD is highly effective and well tolerated in elderly patients (> 65 years) with newly diagnosed multiple myeloma.https://oncohematology.abvpress.ru/ongm/article/view/757bortezomibmultiple myelomatreatmentcomplete remissionoverall survivalneuropathy |
| spellingShingle | S. S. Bessmeltsev L. V. Stelmashenko E. V. Kariagina N. V. Stepanova G. N. Salogub T. L. Shelkovskaya T. A. Malakhova I. A. Skorokhod E. I. Podoltseva N. O. Saraeva O. I. Kovalev A. V. Klimovich N. V. Medvedeva K. M. Abdulkadyrov L. I. Krylova T. H. Potrachkova M. A. Novikova E. R. Machulaitene E. I. Darskaya L. M. Matukhina N. A. Kotova O. Ya. Kostina I. A. Novokreshchenova Modern strategies in therapy of elderly patients with multiple myeloma Онкогематология bortezomib multiple myeloma treatment complete remission overall survival neuropathy |
| title | Modern strategies in therapy of elderly patients with multiple myeloma |
| title_full | Modern strategies in therapy of elderly patients with multiple myeloma |
| title_fullStr | Modern strategies in therapy of elderly patients with multiple myeloma |
| title_full_unstemmed | Modern strategies in therapy of elderly patients with multiple myeloma |
| title_short | Modern strategies in therapy of elderly patients with multiple myeloma |
| title_sort | modern strategies in therapy of elderly patients with multiple myeloma |
| topic | bortezomib multiple myeloma treatment complete remission overall survival neuropathy |
| url | https://oncohematology.abvpress.ru/ongm/article/view/757 |
| work_keys_str_mv | AT ssbessmeltsev modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT lvstelmashenko modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT evkariagina modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT nvstepanova modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT gnsalogub modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT tlshelkovskaya modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT tamalakhova modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT iaskorokhod modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT eipodoltseva modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT nosaraeva modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT oikovalev modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT avklimovich modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT nvmedvedeva modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT kmabdulkadyrov modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT likrylova modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT thpotrachkova modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT manovikova modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT ermachulaitene modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT eidarskaya modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT lmmatukhina modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT nakotova modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT oyakostina modernstrategiesintherapyofelderlypatientswithmultiplemyeloma AT ianovokreshchenova modernstrategiesintherapyofelderlypatientswithmultiplemyeloma |